Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease

El-Haggar, Sahar Mohamed; Mostafa, Tarek Mohamed

doi:10.1007/s12072-015-9633-1

Cited by 44 publications

(28 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, most studies did not assess the effect on liver fibrosis directly. One study did show that fenofibrate reduced liver stiffness and serum hyaluronic acid, a marker of ECM accumulation (El-Haggar and Mostafa, 2015). …”

Section: Peroxisome Proliferator-activated Receptorsmentioning

confidence: 99%

Novel Anti-fibrotic Therapies

McVicker

Bennett

2017

Front. Pharmacol.

View full text Add to dashboard Cite

Fibrosis is a major player in cardiovascular disease, both as a contributor to the development of disease, as well as a post-injury response that drives progression. Despite the identification of many mechanisms responsible for cardiovascular fibrosis, to date no treatments have emerged that have effectively reduced the excess deposition of extracellular matrix associated with fibrotic conditions. Novel treatments have recently been identified that hold promise as potential therapeutic agents for cardiovascular diseases associated with fibrosis, as well as other fibrotic conditions. The purpose of this review is to provide an overview of emerging antifibrotic agents that have shown encouraging results in preclinical or early clinical studies, but have not yet been approved for use in human disease. One of these agents is bone morphogenetic protein-7 (BMP7), which has beneficial effects in multiple models of fibrotic disease. Another approach discussed involves altering the levels of micro-RNA (miR) species, including miR-29 and miR-101, which regulate the expression of fibrosis-related gene targets. Further, the antifibrotic potential of agonists of the peroxisome proliferator-activated receptors will be discussed. Finally, evidence will be reviewed in support of the polypeptide hormone relaxin. Relaxin is long known for its extracellular remodeling properties in pregnancy, and is rapidly emerging as an effective antifibrotic agent in a number of organ systems. Moreover, relaxin has potent vascular and renal effects that make it a particularly attractive approach for the treatment of cardiovascular diseases. In each case, the mechanism of action and the applicability to various fibrotic diseases will be discussed.

show abstract

Section: Peroxisome Proliferator-activated Receptorsmentioning

confidence: 99%

Novel Anti-fibrotic Therapies

McVicker

Bennett

2017

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In particular, despite certain favorable metabolic effects, fibrate monotherapy improves liver histology only to a minimal extent [186][187][188][189][190]. Similarly, PUFA supplementation may ameliorate some metabolic parameters and probably reduces liver fat content, but has no effect on liver inflammation and fibrosis [191][192][193][194][195][196].…”

Section: Fibrates and Polyunstaurated Famentioning

confidence: 99%

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans

et al. 2016

View full text Add to dashboard Cite

show abstract

“…A pilot trial showed improvement of metabolic syndrome and glucose metabolism by fenofibrate in patients with NAFLD but with only minimal effects on liver histology[ 57 ]. Co-treatment with pentoxifylline plus fenofibrate was effective in reduction of liver stiffness and markers of liver fibrosis in patients with NAFLD[ 58 ].…”

Section: Discussionmentioning

confidence: 99%

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease

Eshraghian¹

2017

WJG

View full text Add to dashboard Cite

The main treatment of patients with non-alcoholic fatty liver disease (NAFLD) is life style modification including weight reduction and dietary regimen. Majority of patients are safely treated with this management and pharmacologic interventions are not recommended. However, a subgroup of NAFLD patients with non-alcoholic steatohepatitis (NASH) who cannot achieve goals of life style modification may need pharmacological therapy. One major obstacle is measurement of histological outcome by liver biopsy which is an invasive method and is not recommended routinely in these patients. Several medications, mainly targeting baseline mechanism of NAFLD, have been investigated in clinical trials for treatment of NASH with promising results. At present, only pioglitazone acting as insulin sensitizing agent and vitamin E as an anti-oxidant have been recommended for treatment of NASH by international guidelines. Lipid lowering agents including statins and fibrates, pentoxifylline, angiotensin receptor blockers, ursodeoxycholic acid, probiotics and synbiotics are current agents with beneficial effects for treatment of NASH but have not been approved yet. Several emerging medications are in development for treatment of NASH. Obeticholic acid, liraglutide, elafibranor, cenicriviroc and aramchol have been tested in clinical trials or are completing trials. Here in, current and upcoming medications with promising results in clinical trial for treatment of NAFLD were reviewed.

show abstract

Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease

Cited by 44 publications

References 73 publications

Novel Anti-fibrotic Therapies

Novel Anti-fibrotic Therapies

The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease

Contact Info

Product

Resources

About